Meeting
2022 ASCO Annual Meeting
Variation of use of targeted therapies and molecular diagnostic testing by practice type for non-small cell lung cancer and colorectal cancer.
Authors
Thomas Roberts
Dana–Farber Cancer Institute, Boston, MA
Thomas Roberts , Kenneth L. Kehl , Gabriel A. Brooks , Lynette M. Sholl , Alexi A. Wright , Barbara Bai , Mary Beth Landrum , Nancy Lynn Keating
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Access to Care
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6551)
DOI
10.1200/JCO.2022.40.16_suppl.6551
Abstract #
6551
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Disparities in clinical trial participation beyond first-line treatment among patients with metastatic breast or colorectal cancer.
First Author: Jennifer S. Wang
Poster
2023 ASCO Quality Care Symposium
Biomarker testing rates among metastatic cancer patients with receipt of anti-cancer systemic therapy: A real-world data analysis.
First Author: Stacey DaCosta Byfield
Poster
2023 ASCO Annual Meeting
Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.
First Author: Anne Hansen Ree
Poster
2023 ASCO Annual Meeting
LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.
First Author: Ryan Huu-Tuan Nguyen